NFAT1 and JunB Cooperatively Regulate IL-31 Gene Expression in CD4\(^+\) T Cells in Health and Disease

Ji Sun Hwang, Gi-Cheon Kim, EunBee Park, Jung-Eun Kim, Chang-Suk Chae, Won Hwang, Changhon Lee, Sung-Min Hwang, Hui Sun Wang, Chang-Duk Jun, Dipayan Rudra and Sin-Hyeog Im

*J Immunol* published online 16 January 2015
http://www.jimmunol.org/content/early/2015/01/16/jimmunol.1401862

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2015/01/16/jimmunol.1401862.DCSupplemental

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
NFAT1 and JunB Cooperatively Regulate IL-31 Gene Expression in CD4+ T Cells in Health and Disease

Ji Sun Hwang,* Gi-Cheon Kim,*† EunBee Park,* Jung-Eun Kim,*† Chang-Suk Chae,* Won Hwang,*† ChangHoon Lee,*† Sung-Min Hwang,*† Hui Sun Wang,§ Chang-Duk Jun,† Dipayan Rudra,* and Sin-Hyeog Im*†

IL-31 is a key mediator of itching in atopic dermatitis (AD) and is preferentially produced by activated CD4+ T cells and Th2 cells. Although pathophysiological functions of IL-31 have been suggested in diverse immune disorders, the molecular events underlying IL-31 gene regulation are still unclear. In this study we identified the transcription start site and functional promoter involved in IL-31 gene regulation in mouse CD4+ T cells. TCR stimulation–dependent IL-31 expression was found to be closely linked with in vivo binding of NFAT1 and JunB to the IL-31 promoter. Although NFAT1 alone enhanced IL-31 promoter activity, it was further enhanced in the presence of JunB. Conversely, knockdown of either NFAT1 or JunB resulted in reduced IL-31 expression. NFAT1-deficient CD4+ T cells showed a significant defect in IL-31 expression compared with wild-type CD4+ T cells. In agreement with these findings, mice subjected to atopic conditions showed much higher levels of IL-31, which were closely correlated with increased expression of IL-31 in infiltrated NFAT1+CD4+ T cells into the AD ears. Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4+ T cells and total ear residual cells. In summary, our results suggest a functional cooperation between NFAT1 and JunB in mediating IL-31 gene expression in CD4+ T cells and indicate that interference with this interaction or their activity has the potential of reducing IL-31–mediated AD symptoms.

The Journal of Immunology, 2015, 194: 000–000.

**Academy of Immunology and Microbiology, Institute for Basic Science, Pohang 790-784, Republic of Korea; †School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Republic of Korea; ‡Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang 790-784, Republic of Korea; †Department of Neurosurgery, Chosun University College of Medicine, Gwangju 501-717, Republic of Korea. Received for publication July 21, 2014. Accepted for publication December 14, 2014.

This work was supported by a research program of the Institute for Basic Science (Grant IBS-R005-G14-2014-a00) and by Agricultural Science and Technology Development Grant PP017153, National Academy of Agricultural Science, Rural Development Administration, Republic of Korea.

Address correspondence and reprint requests to Dr. Sin-Hyeog Im, Academy of Immunology and Microbiology, Institute for Basic Science/Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang 790-784, Republic of Korea. E-mail address: imsh@postech.ac.kr

The online version of this article contains supplemental material.

Abbreviations used in this article: AD, atopic dermatitis; CA, constitutively active; ChIP, chromatin immunoprecipitation; CsA, cyclosporin A; DAPA, DNA affinity purification assay; DNBC, 2,4-dinitrochlorobenzene; HPRT, hypoxanthine phosphoribosyltransferase; KO, knockout; mt, mutated; NGS, normal goat serum; OSMR, oncostatin M receptor-β; PLX, proximity ligation assay; qRT-PCR, quantitative RT-PCR; siRNA, small interfering RNA; TSS, transcription start site; WT, wild-type.

Copyright © 2015 by The American Association of Immunologists, Inc. 0022-1767/15/S25.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1401862
factors responsible for IL-31 gene expression in CD4+ T cells. We showed that recruitment of NFAT1 and JunB proteins to the IL-31 promoter locus significantly enhanced IL-31 promoter activity. In experimental AD, infiltrated CD4+ T cells that produce high levels of IL-31 expression also showed high NFAT1 levels. Additionally, oral administration of cyclosporin A (CsA) to AD mice significantly suppressed disease progression by decreasing IL-31 expression in CD4+ T cells as well as total ear residual cells.

Materials and Methods
Mice and cell lines
Female BALB/c mice (6–8 wk of age) and C57BL/6 mice (6–8 wk of age) were purchased from Japan SLC (Hamamatsu, Japan). An NFAT1-deficient mouse line was provided by Dr. A. Rao (La Jolla Institute for Allergy and Immunology). All mice were maintained under specific pathogen-free conditions in the Animal Facility of the Gwangju Institute of Science and Technology. All experimental procedures were performed in accordance with National Institutes of Health’s Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care and Ethics Committees of the Gwangju Institute of Science and Technology (permit no. GIST-2011-3). Animals were maintained in accordance with the National Animal Welfare Law of Korea. The murine T cell lymphoma cell line EL4 was obtained from the Korea Cell Line Bank (Seoul National University, Seoul, Korea). Human embryonic kidney cell line HEK-293 was purchased from Invitrogen (Grand Island, NY).

Cell culture and stimulation
Isolated primary cells were cultured in RPMI 1640 medium (Welgene, Daegu, Korea) supplemented with 10% FBS (HyClone Laboratories, Logan, UT), 3 mM 2-glutamine (Sigma-Aldrich, St. Louis, MO), 100 U/ml penicillin (Sigma-Aldrich), 100 U/ml streptomycin (Sigma-Aldrich), nonessential amino acids (Welgene), sodium pyruvate (Welgene), HEPES (Welgene), and 0.05 mM 2-ME (Sigma-Aldrich). Ear total cells were cocultured with CD4+ T cell–depleted splenocytes with house dust mite extracts (5 μg/ml) for 24 h. CD4+ T cells were stimulated with PMA (50 ng/ml) and/or ionomycin (1 μM) for 2 h. CD4+ T cells were also stimulated with 1 μg/ml plate-bound anti-CD3 (BD Biosciences, San Diego, CA), 1 μg/ml soluble anti-CD28 (BD Biosciences), or anti-CD3/anti-CD28 for 2 h. To check IL-31 mRNA expression kinetics, cells were stimulated with PMA/ionomycin or anti-CD3/anti-CD28 for the indicated time points. NFAT1-deficient CD4+ T cells were stimulated with PMA/ionomycin for indicated time points to compare IL-31 expression with normal CD4+ T cells. For the inhibitor experiments, CD4+ T cells isolated from C57BL/6 mice or AD-induced mice were pretreated with 1 μM CsA (Calbiochem, Darmstadt, Germany), 5 μM tanshinone IIA (Santa Cruz Biotechnology, Santa Cruz, CA), CsA/tanshinone IIA, or activator protein 1 (AP-1)–specific inhibitors for an additional 2 h.

Isolation of CD4+ T cells and total ear residual cells
CD4+ T cells from the lymph nodes and spleen of C57BL/6 mice were isolated with CD4+ T cell isolation beads according to the manufacturer’s protocol. Ear tissues were removed from normal or AD groups, cut into three pieces, washed with RPMI 1640 medium (Welgene), and gently stirred in flasks containing 25 ml 1.0 mM EDTA in 5% FBS (HyClone Laboratories) for 20 min at room temperature. Then ear segments were minced, transferred into a 50-ml centrifuge tube containing 15 ml RPMI 1640 without serum, and vigorously shaken for 15 s three times. After that, tissues were transferred into T flasks containing 10 ml 0.5 mg/ml collagenase type V (Sigma-Aldrich) and incubated for 1 h at 37˚C in a shaking incubator. Finally, the soup containing ear total cells was centrifuged and washed with ice-cold PBS and cultured in T cell media. Ear residual CD4+ T cells were isolated with CD4+ T cell isolation beads according to the manufacturer’s protocol, and flow-through was used as non–CD4+ T cells.

RACE
5'RACE was carried out by using the SMARTer RACE cDNA amplification kit (Clontech Laboratories, Mountain View, CA) according to the manufacturer’s instructions. The primer sequences used are as follows: first PCR (5′-CCA CTT CCA GTC CCT ACA AGG TAG CAG AAC AAG ATT TCA-3′), nested PCR (5′-TAA CAT GAC TAG TAA TCA CCG CAC AGT-3′). The resulting RACE PCR products were isolated from agarose gel by using the NucleoTrap gel extraction (Clontech), cloned into pGEM-T Easy vector (Promega, Madison, WI), and confirmed by sequencing.

RNA isolation, cDNA synthesis, and quantitative real-time PCR
Total RNA was extracted from cells with TRizol reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer’s protocol. For reverse transcription, 1 μg total RNA was used and cDNA was generated using an oligo(dT) primer (Promega) and ImPromII reverse transcriptase (Promega) in a total volume of 20 μl. The mRNA level was determined using 1 μl cDNA in a real-time PCR with SYBR Green as a protocol provided by the manufacturer (Chromos; MJ Research). Mouse hypoxanthine phosphoribosyltransferase (HPRT) primer was used for quantitative RT-PCR (qRT-PCR) to normalize the amount of cDNA used for each condition. The primer sequences used are as follows: HPRT (forward, 5′-TTG TGG ACA GTA GGT AAA CAG-3′, reverse, 5′-GCT TTA CTT TAA AGC TCA GTC-3′), IL-31 (forward, 5′-ACA ACT ATA GCA TAA AGC CAG-3′, reverse, 5′-GAT TCA TTA GTT TTT CCA GGC A-3′), NFAT1 (forward, 5′-GAG AAG ACT ACA GAT GGG CAG-3′, reverse, 5′-ACT GGG TAG TAG GTA AGG TGC-3′), and JunB (forward, 5′-AGG TGA ACA CAC TGA AGG CAT A-3′, reverse, 5′-TGA CAT GGG TCA TCT CCT GCT T-3′).

Plasmid construction, site-directed mutagenesis, and luciferase reporter assays
The deletion constructs were generated by cloning the genomic sequences upstream of the first coding exon of the IL-31 gene into the pXPurr vector digested by appropriate restriction enzymes. Different combinations of forward primers and same reverse primer in the 5′ region of the translation start site were included in the IL-31 promoter construct, or the indicated reporter vector was subjected to site-directed mutagenesis. Primers used for the generation of mutant constructs are as follows (mutated regions are underlined): mutated (nt) NFAT-1a, forward, 5′-GCA TTT TGG TAA AAA GTG CTG TGG AAA AAG TCA GC-3′, reverse, 5′-GCT CAT TCT CAT CAT CAT TAA CAG TCC CAT CC-3′; mutated (nt) NFAT-1b, forward, 5′-GAAG GA-3′, reverse, 5′-GCAG CTT TGC TAA CGA CAT TTT C-3′; NFAT-1c, forward, 5′-GAAG AAG TCG TCT CTA AGC CAT C-3′, reverse, 5′-GCC ATG GCG TGG TGC TCT CTT CTA TCT TGG-3′; NFAT-1d, forward, 5′-GAG AAC AGG TCG TTT CCT CAT CTC-3′, reverse, 5′-GCG GCT TCT TCG TCT CTT CTA CTA CTA-3′; NFAT-1e, forward, 5′-GAG GAA TCA ATG GGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1f, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1g, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1h, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1i, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1j, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′; NFAT-1k, forward, 5′-GAG AAC AGG TCA TTT ACT CAT T-3′, reverse, 5′-GCC AAC TAT TCA SSA GAT GTA CAT CTA-3′.

Plasmid DNAs were prepared by Gene All Exprep Plasmid kit (GeneAll Biotechnology, Seoul, Korea) and EL4 T cells were transiently transfected by GeneExpresso (Excellgen, Rockville, MD) according to the manufacturers’ protocols. The total amount of transfected DNA for each sample was normalized by adding the control vector, pCDNA. After 18 h, cells were stimulated with PMA/ionomycin for 6 h and then luciferase activity was accessed by the Dual-Luciferase assay system (Promega, Madison, WI). Cotransfection of the HRE-luciferase vector as an internal control allowed normalization of transfection by Renilla luciferase activity. Constitutively active (CA)-NFAT1– and mutated (mt) NFAT1–expressing vectors were given to us by Dr. A. Rao (La Jolla Institute for Allergy and Immunology). CA-NFAT1 or mtCA-NFAT1 construct was transfected with the IL-31 promoter containing reporter plasmid to EL4 T cells in the presence or absence of JunB expression vector, and following steps are same as previously described.

Proximity ligation assay
The in situ PLA proximity ligation assay (PLA; Duolink in situ fluorescence kit, Olink Bioscience, Uppsala, Sweden) was used to detect the interaction between NFAT1 and JunB in CD4+ T cells. Wild-type (WT) CD4+ T cells or NFAT1 knockout (KO) CD4+ T cells were stimulated with or without anti-CD3, anti-CD28, and PMA/ionomycin, followed by fixation with PFA, permeabilized, and incubated with the indicated primary Abs and the PLA probes (anti-murine and anti-rabbit IgG Abs conjugated with oligonucleotides). Ligation and
amplification were performed according to the manufacturer's instructions. Imaging was performed on fixed samples with a confocal laser scanning microscope Zeiss LSM 700 (>63 oil immersion objective).

Chromatin immunoprecipitation assay

Chromatin immunoprecipitation (ChIP) analysis was carried out essentially as described (22) with minor modifications. CD4+ T cells isolated from WT and NFAT1-deficient mice were harvested and fixed with formaldehyde after treating with or without PMA/ionomycin for 2 h prior to harvest. Chromatin was immunoprecipitated using anti-NFAT1 Ab (Santa Cruz Biotechnology), anti-JunB Ab (Santa Cruz Biotechnology), or rabbit IgG Ab (Sigma-Aldrich). Following reversal of crosslinks, presence of the selected DNA sequence was assessed by real-time PCR using SYBR Green PCR mix. The primer sequences used in ChIP are as follows: −359/−242 region, forward, 5′-CTG TAC TCA CTT CTT CC-3′, reverse, 5′-CAA GCC AGA AGA TGG AGT CAC-3′; −116/−53 region, forward, 5′-ATC TTC TGC CTT CTT TTG AG-3′, reverse, 5′-ATG AGG AAG CAG TTC AAA GG-3′; −1374/−1179 region, forward, 5′-AAA TAA AGA GTC GTT CAG CCA GG-3′, reverse, 5′-AGT GAT CAA TTA GCC CCT-3′. As a loading control, the PCR was done directly on input DNA purified from chromatin before immunoprecipitation. Data are presented as the amount of DNA recovered relative to the input control.

DNA affinity purification assay

A DNA affinity purification assay (DAPA) was performed following protocols described previously with minor modifications (21). Briefly, biotinylated complementary oligonucleotides were annealed in TEN (10 mM Tris/His [pH 8.0], 1 mM EDTA, 100 mM NaCl) buffer. HEK-293 cells overexpressing NFAT1 or JunB were lysed by sonication in 200 μl Hongko buffer (10 mM HEPES [pH 7.9], 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% Nonidet P-40, and 1 mM DTT) buffer containing protease and phosphatase inhibitors (Roche Applied Science). The cellular debris was removed by centrifugation. After that 30 μg total cell lysate was incubated with anti-NFAT1, anti-JunB, and anti–β-actin (Abcam, Cambridge, MA) Abs to check the expression level of NFAT1 and JunB along with that of β-actin (control) by immunoblotting. The cell extracts (500 μl) were pre-cleared with 10 μl M-280 streptavidin beads (Invitrogen) for 1 h at 4°C with gentle agitation. The cleared nuclear extracts were then incubated with 1 μg biotinylated double-stranded probes and 10 μg poly(dI-dC) overnight. Ten micromolars M-280 streptavidin beads was used to pull down bound proteins for 1 h at 4°C with gentle agitation. The beads were washed four times with cold HKMG buffer. SDS sample buffer was then added to the beads. The samples were boiled for 5 min and subjected to SDS-PAGE and Western blotting with anti-NFAT1 and anti-JunB (Santa Cruz Biotechnology) Abs. Blots were developed using HRP-conjugated secondary Ab (Sigma-Aldrich) and the an ECL Western blot detection kit (Amersham Pharmacia Biotech, Arlington Heights, IL). The probe sequences used for DAPA are as follows: NFAT-a, forward, 5′-CTA GCC CTT TCT AAC AAG GAG GAT-3′; reverse, 5′-AGT GAT CAA TTA GCC CCT-3′; NFAT-b, forward, 5′-CCA CTT TTT GAA ATT GTC TTT TGG AGA AAA-3′; reverse, 5′-TTT TCT CCA GAA AAC ATT TTC AAA AGG TTG TTG-3′; NFat-c, forward, 5′-AAG CTG AGC AGT GGT TTT GCC ATG ATG GGG-3′, reverse, 5′-GCC CCC CAT GCC AAA ACC ATT CCT CAG CTT-3′; NFAT; forward, 5′-CCG GGA GAT TTT CAT-3′, reverse, 5′-ACG GAA TTC TTT CTT CTT GCC CCT-3′; AP-1, forward, 5′-TTT CAT CTT TAA ATC AGG AAC CAC TTT CCA-3′, reverse, 5′-TGG AAA GGA ATG CTT GAT CTT GAT TTA ATG AGA GGA-3′; AP-1, forward, 5′-TTT GCT GAA AAG AGT AAG GAT TTT G-3′, reverse, 5′-CCA AAC CAT TGC TCA GCT TTT TCT CCA-3′; mNFAT-a, forward, 5′-CCA GCA GGC GCG AGA AAA AGA AGAT G-3′, reverse, 5′-GCA TCT CTC TCT GCC CTT GTG CTT G-3′; mNFAT-b, forward, 5′-GAA CAT TTT GAA AAT GTT GTT ATG AGA AAA-3′, reverse, 5′-TTT TCT AAT GAA AAT CCT TTT AGG TTG-3′; mNFAT-c, forward, 5′-AAG CTG AGC GAT GGT TTT GCC ATG ATG GGG-3′, reverse, 5′-GCC CCC CAT GCC CCC ACC ATT CCT CAG CTT-3′; mAP-1, forward, 5′-AAG CTG AGC GAT GGT GGC ATG ATG GGG-3′, reverse, 5′-GCC CCC CAT GCC CCC ACC ATT CCT CAG CTT-3′; mNFAT, forward, 5′-TGC GAA GGA AAG AGT CTC GAT AAT GGT-3′, reverse, 5′-CAG AAC CAT TGA GAC GCT CTT CTC CAG-3′.

Small interfering RNA transfection assay

The predesigned small interfering RNAs (siRNAs) for NFAT1 (sc-36056), JunB (sc-35727), and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. For siRNA transfection, effector T cells were subjected to nucleofection (Amaxa Nucleofector; Lonza, Walkersville, MD) according to the manufacturer's protocol. Briefly, effector T cells were resuspended in mouse T cell nucleofection solution at a density of 2 × 10^6 per 100 μl. In each transfection, 100 μl cell suspension was mixed with 1 μM siRNA, transfected into a cuvette, and pulsed in a Nucleofector device using program X-001. The cells were then transfected into a 12-well plate and plated in 1 ml prewarmed medium. Forty-six hours after transfection, the cells were treated with PMA/ionomycin for 2 h and harvested. mRNA isolation and cDNA synthesis was performed following the protocol described before, and knockdown efficiency was determined by qRT-PCR and Western blot. Relative band intensity (intensity of NFAT1 or JunB/intensity of β-actin) of each sample was analyzed by ImageJ software. For ChIP analysis, effector T cells were transfected with control siRNA or JunB siRNA. Forty-six hours after transfection, the cells were stimulated with PMA/ionomycin for 2 h and harvested to perform an NFAT1 ChIP assay.

NFAT overexpression and reconstitution

Isolated CD4+ T cells from WT C57BL/6 or NFAT1-deficient mice were stimulated with anti-CD3/anti-CD28 in the presence of rIL-2 (100 U/ml) for 3 d, then cultured in only IL-2–containing complete T cell media. NFAT1, JunB, or NFAT1 and JunB were transfected into effector T cells by an Amaxa Nucleofector (Lonza) according to the manufacturer’s protocol. After 22 h of transfection, the cells were stimulated with PMA/ionomycin for 2 h and IL-31 mRNA level was measured by real-time PCR. In this experiment, GFP expressing vector was used as a control. Protein expression levels of each sample were analyzed by Western blot. Whole-cell lysates were loaded to perform an NFAT1 ChIP assay.

Preparation of total cell lysate and nuclear extracts

Cells were washed with ice-cold PBS and resuspended in RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate) containing protease inhibitors and 1% Nonidet P-40. Cells were allowed to swell by incubation on ice for 20 min, and then the homogenate was centrifuged for 5 min. The supernatant containing total cell lysate was transferred to new tubes and used for immunoblotting. Nuclear extract was prepared with NE-PER nuclear and cytoplasmic extraction reagents (Thermo scientific, Waltham, MA) according to the manufacturer's protocol. The supernatant containing nuclear extract was used for immunoblotting.

Induction of AD and treatment of CsA

Induction of experimental AD was performed by following a protocol described previously (23). Briefly, surfaces of both ear lobes of female BALB/c mice (6–8 wk of age) were stripped five times with surgical tape (Nichiban, Tokyo, Japan). After stripping, 20 μl 2% 2,4-dinitrochlorobenzene (DNCB) (Sigma-Aldrich) dissolved in acetone/olive oil (1:3) solution was painted on each ear. After 3 d, 20 μl 10 mg/ml mite extract (Dermatophagoides farinae; GREER, Lenoir, NC) dissolving in PBS containing 0.5% Tween 20 was repainted. Challenge of DNCB and mite extract was repeated once a week alternatively until 5 wk. Only tape stripping and DNCB painting were performed in the normal group. To examine the effect of CsA, the micro-emulsion form of CsA (5 mg/kg/d; Novartis, New York, NY) was orally administrated to BALB/c mice 5 d/wk for 4 wk during the period of AD induction. The same volume of DMSO was treated as a control.

Immunohistochemistry

Ears from AD-induced mice, normal mice, control AD-induced mice, and CsA-treated AD-induced mice were fixed with 4% paraformaldehyde in PBS (10% sucrose in PBS). Fixed tissues were washed in sucrose solution (10% sucrose in PBS for 4 h, 15% sucrose in PBS for 4 h, and 20% sucrose in PBS overnight) and were frozen in OCT compound (Sakura Finetek, Leiden, The Netherlands). Cryostat sections (10 μm) were mounted on Superfrost Plus slides and dried overnight at room temperature. Slides were permeabilized with 0.1% Triton X-100 in 1% normal goat serum (NGS) for 15 min and blocked with 5% NGS for 1 h at room temperature. After washing with PBS, sections were further incubated with the following corresponding secondary Abs: Alexa Fluor 405 goat anti-rabbit IgG (1:1000, Invitrogen), and Alexa Fluor 594 goat anti-mouse IgG (1:1000, Invitrogen). They were then washed with PBS and the sections were incubated for 1 h at room temperature with the following corresponding secondary Abs: Alexa Fluor 405 goat anti-mouse IgG (1:1000; Invitrogen), Alexa Fluor 488 donkey anti-rabbit IgG (1:1000; Invitrogen), and Alexa Fluor 594 goat anti-mouse IgG (1:1000, Invitrogen). Nucleus was counterstained with DAPI (1:3000; Invitrogen) for 5 min at room temperature. Sections were washed and then mounted with fluorescent mounting medium (Dako, Seoul, Korea).
Computational analysis of the conserved nucleotide sequence locus

To identify a potential regulatory locus, comparative genomic analysis was performed. Genomic sequences spanning the IL-31 gene were analyzed using the Web-based alignment software VISTA browser 2.0 (23). Transcription factor binding sites were identified using the rVISTA 2.0 software (24), which uses matrices of the TRANSFAC database (25). Putative recognition sites for regulatory factors were also identified by searching the JASPAR database (26) and verified from previously reported literature.

Statistical analysis

A two-tailed Student t test was used. A p value <0.05 was considered statistically significant.

Results

TCR stimulation–dependent IL-31 gene expression

To investigate the underlying mechanism of IL-31 gene expression in CD4+ T cells, we analyzed the IL-31 mRNA expression profile. CD4+ T cells isolated from spleen and lymph nodes of C57BL/6 mice were either unstimulated or stimulated with TCR signaling (anti-CD3/anti-CD28) or PMA/ionomycin, along with related controls. Relative levels of IL-31 mRNA expression were analyzed by qRT-PCR. IL-31 expression was significantly increased upon anti-CD3/anti-CD28 or PMA/ionomycin stimulation (Fig. 1A). To test whether IL-31 expression is regulated at the transcriptional level, we tested the effect of actinomycin D, an inhibitor of mRNA synthesis. Indeed, pretreatment with actinomycin D significantly decreased IL-31 mRNA expression upon PMA/ionomycin stimulation (Fig. 1B). Next, we determined the expression kinetics of IL-31 mRNA expression. CD4+ T cells were stimulated with anti-CD3/anti-CD28 or PMA/ionomycin for the indicated time points. Stimulation with PMA/ionomycin or anti-CD3/anti-CD28 for 2 h significantly increased IL-31 mRNA expression (PMA/ionomycin, 290-fold; anti-CD3/anti-CD28, 105-fold) (Fig. 1C). To determine whether IL-31 expression is regulated at the transcriptional level, we tested the effect of actinomycin D on mRNA synthesis. Indeed, pretreatment with actinomycin D significantly decreased IL-31 mRNA expression (Fig. 1B). Next, we determined the expression kinetics of IL-31 mRNA expression. CD4+ T cells were stimulated with anti-CD3/anti-CD28 or PMA/ionomycin for the indicated time points. Stimulation with PMA/ionomycin or anti-CD3/anti-CD28 for 2 h significantly increased IL-31 mRNA expression (PMA/ionomycin, 290-fold; anti-CD3/anti-CD28, 105-fold) (Fig. 1C).

Identification of the transcription start site and promoter region

To identify the transcription start site (TSS) at the mouse IL-31 gene locus, we employed the SMART 5′-RACE technique. mRNA isolated from CD4+ T cells was amplified with the gene-specific primer (corresponds to the exon 3 region of the IL-31 gene) and the universal primer mix (Fig. 2A). RACE PCR produced one major IL-31 transcript in CD4+ T cells (Fig. 2B). To determine the location of the TSS, RACE transcript was isolated, sequenced, and alignment of the sequenced RACE products to the mouse genome was performed along with GenBank (GenBank accession no. NM_029594; http://www.ncbi.nlm.nih.gov/nuccore/NM_029594.1). TSS was aligned with 60 bp upstream of translation start site, ATG (Fig. 2C). Next, to identify the potential regulatory elements in the 5′ region of the IL-31 gene, we performed a comparative genomic sequence analysis. rVISTA 2.0 and TRANSFAC database analysis revealed several potential regulatory elements that have highly conserved noncoding sequences between humans and mice (Fig. 3A). These include TSS, TATA box, and predicted transcription factor binding sites (Fig. 3B). To identify the core cis-regulatory elements we generated a series of deletion constructs as depicted in Fig. 3C. These constructs were transiently transfected into EL4 T cells, and their relative reporter activities were compared. The functional promoter region was mapped in the −359/+141 region (498-bp construct) that showed maximal promoter activity upon PMA/ionomycin stimulation (Fig. 3C). Interestingly, further deletion of the functional promoter region significantly decreased its promoter activity as shown in the −242/+141 region (381-bp construct) and the −53/+141 region (194-bp construct), suggesting that the −359/+141 region may serve as a core IL-31 promoter in CD4+ T cells.

Functional cooperation between NFAT1 and JunB to activate IL-31 expression

To identify the key transcription factors responsible for TCR stimulation–dependent IL-31 promoter activity, we performed sequence analysis of the identified −359/+141 functional promoter region of the IL-31 gene. Indeed, we could identify highly conserved binding sites for AP-1, NFAT, and NF-κB (Fig. 3B). To delineate which transcription factors play a major role in activation of IL-31 promoter, a luciferase reporter assay was performed in the presence of different combinations of transcription factors.
EL4 T cells were transiently transfected with an IL-31 promoter–driven luciferase construct along with empty vector, vectors encoding members of the AP-1 family (JunB, c-Jun, and c-Fos), or NFAT family (NFAT1, NFAT2, and NFAT4). Among them, NFAT1 overexpression significantly enhanced IL-31 promoter activity (Fig. 4A) in a dose-dependent manner (Fig. 4B). However, other factors such as NFAT2, NFAT4, JunB, c-Jun, and c-Fos failed to activate the IL-31 promoter (Fig. 4A). Because NFAT protein functions with other interacting partners to regulate its target gene expression (27), we tested whether NFAT1 could further enhance its IL-31 transcriptional activity through a coordinate interaction with AP-1 protein that has a binding site near the NFAT binding site at the IL-31 promoter (Fig. 3B). An IL-31 promoter–driven luciferase construct was transfected with NFAT1 alone or in combination with each family of AP-1 proteins, and transactivity was measured by a luciferase assay. Cotransfection of NFAT1 and JunB synergistically increased promoter activity compared with the activity of single transfection (Fig. 4C). Even though c-Jun and c-Fos also showed

---

**FIGURE 3.** Identification of the functional promoter region of the IL-31 gene. (A) ECR browser analysis of the mouse and human IL-31 loci is shown. The mouse genomic sequence is used as the base sequence on the x-axis. Schematic representation of the genomic positions of exons (E) and putative binding sites of transcription factors and TATA box in the 5′-end region of the IL-31 gene are shown. (B) 5′-End genomic sequence of mouse IL-31 gene locus with TSS indicated in bold type and black arrow and designated as +1. Locations of the deletion constructs are indicated in blue. TATA box (TATA), translation start site (ATG), and putative binding sites for transcription factors (AP-1, NFAT, and NF-κB) are indicated and boxed. STAT6 binding site in the human IL-31 promoter is underlined in red. (C) EL4 T cells were transfected with the control mock vector or indicated deletion constructs. Cells were unstimulated or stimulated with PMA/ionomycin for 6 h and then relative luciferase activity (RLA) was expressed as fold difference relative to the unstimulated mock sample. The genomic location and size of each deletion construct are specified. Error bars indicate SD. Data are representative of three independent experiments. *p < 0.05, **p < 0.005.
a synergistic effect with NFAT1 in IL-31 promoter activity, JunB showed a more significant effect compared with other AP-1 proteins. Therefore, we decided to focus on the synergistic effect between NFAT1 and JunB for IL-31 gene expression. We also tested whether STAT6 could activate the mouse IL-31 promoter because STAT6 was reported as a key transcription factor for enhancing the human IL-31 promoter activity (24). Unlike in the human IL-31 promoter, NFAT2 and STAT6 failed to activate the mouse IL-31 promoter, and NFAT1 alone sufficiently activated the mouse IL-31 promoter in a STAT6-independent manner (Supplemental Fig. 1 B). Overexpression of constitutively active form of NFAT1 (25) enhanced IL-31 promoter activity and cotransfection of CA-NFAT1 and JunB further enhanced IL-31 promoter activity. However, cotransfection of mtCA-NFAT1 (25), a mutant CA-NF1 that has a mutation in the AP-1 binding sites, with JunB failed to exert a functional synergism (Fig. 4 D). Deletion of NFAT and AP-1 binding sites in the functional promoter (−359/−116 region) significantly reduced its promoter activity as observed in the −116/+141 region (257-bp construct) reporter vector (Fig. 4 E). To further confirm the importance of NFAT and AP-1 transcription factors on IL-31 promoter activity, NFAT or AP-1 (JunB) binding sites were mutated in the functional promoter (−359/+141 region) individually or in combination as shown in Fig. 4 F. Promoter activity was significantly decreased when a mutation was introduced in the NFAT binding site located in the −359/−116 region and −116/+141 region. In the case of AP-1 (JunB), single mutation of each AP-1 binding site decreased the promoter activity. Interestingly, IL-31 promoter activity was significantly reduced when all of the NFAT and AP-1 binding sites were mutated (Fig. 4 F). These results suggest that although NFAT1 plays a major role in activation of IL-31 promoter, AP-1 (JunB) provided an additive effect on TCR-induced IL-31 promoter activity.

Physical binding of NFAT1 and JunB to the IL-31 promoter locus

To test whether the functional synergism between NFAT1 and JunB results from protein–protein interaction between them, we performed a PLA in CD4+ T cells. Under unstimulated condition, a PLA signal was detected only in the cytoplasmic region, and more distinct signals were observed in the nucleus upon PMA/ionomycin stimulation (Fig. 5 A). In contrast, there was no detectable PLA signal when WT CD4+ T cells were incubated with only NFAT1 Ab (Fig. 5 B) or NFAT1 KO CD4+ T cells that were incubated with both NFAT1 and JunB Abs (Fig. 5 C). These results suggest that NFAT1

![FIGURE 4.](http://www.jimmunol.org/)

NFAT1 and JunB cooperatively transactivate the IL-31 promoter. (A–C) EL4 cells were transfected with control vector (mock) or luciferase reporter constructs driven by the IL-31 promoter (−359/−141 region, 498-bp construct) along with expression plasmids encoding NFATs (NFAT1 [N1], NFAT2 [N2], and NFAT4 [N4]), AP-1 (JunB [JB], c-Jun [CJ], and c-Fos [CF]), and NF-kB (p65) (NK) or their combinations as indicated. Cells were stimulated with PMA/ionomycin for 6 h and harvested for luciferase assay. (B) The NFAT1 dose-dependent effect was analyzed (300 [+], 600 [++], and 900 [+++] ng). Cells were stimulated with PMA/ionomycin for 6 h and harvested for the luciferase assay. (D) EL4 cells were transfected with luciferase reporter construct driven by the IL-31 promoter along with expression plasmids encoding CA-NFAT1 (CA-NF1) or mtCA-NFAT1 (mtCA-NF1, which has mutations in AP-1 binding site) in the presence or absence of JunB-expressing plasmid, as indicated. Cells were stimulated with PMA/ionomycin for 6 h and harvested for the luciferase assay. Relative luciferase activity (RLA) of each sample to control sample (mock) is presented. (E) The 257-bp construct (−116/+141 region) or 498-bp construct (−359/+141 region) was transfected to EL4 cells along with the indicated expression plasmids, stimulated with PMA/ionomycin, and then the relative luciferase assay was measured. The binding sites for AP-1 (filled triangle) or NFAT (gray-filled circle) are shown. (F) Various combinations of mutations were introduced into the IL-31 promoter reporter construct as indicated: X, mutated site in NFAT1 (N) or JunB (A) binding sites in Fig. 3 B; mtNα, mtNβ, mtNc, mtNbNc; and mtNaNbNc indicate mutations in the NFAT binding sites alone or in combination in NFAT-a, NFAT-b, and NFAT-c, respectively; mtAA, mtAb, and mtAAAb indicate mutations in the AP-1 binding sites alone or in combination in AP-1-a and AP-1-b, respectively; mtNαNc indicates mutations in NFAT-a and AP-1–a; mtNbNbc indicates mutations in NFAT-b, AP-1–b and NFAT-c; mt all indicates mutations in all of the AP-1 and NFAT1 binding sites. Each mutant construct was transfected in EL4 cells, stimulated with PMA/ionomycin for 6 h, and then the RLA was measured. RLA activity was expressed as a fold difference relative to the control sample (mock). Error bars indicate SD. Data are representative of three independent experiments. *p < 0.05, **p < 0.005, ***p < 0.001.
and JunB interact in primary CD4+ T cells. Following this, to detect a physical binding of NFAT1 to the predicted NFAT binding sites on the IL-31 promoter, we performed ChIP experiments using Abs for NFAT1 and JunB. In vivo binding of NFAT1 (Fig. 6A) and JunB (Fig. 6B) to the −359/−116 and −116/−53 region was confirmed in CD4+ T cells, and their binding to the loci was further enhanced

**FIGURE 5.** Physical interaction between NFAT1 and JunB in primary CD4+ T cells. (A) NFAT1/JunB association was visualized in WT CD4+ T cells with an in situ proximity ligation assay as described in Materials and Methods. CD4+ T cells were stimulated with (+) or without (−) PMA/ionomycin (P/I) for 2 h, after which they were subjected to PLA. Red staining indicates an NFAT1/JunB interaction, and DAPI was used to visualize the nuclei (blue). (B) WT CD4+ T cells were treated as described in (A) without anti-JunB Ab. (C) NFAT1 KO CD4+ T cells were used and all of the procedures were same as is (A). The top panels are overviews at lower magnification, whereas in the lower panels images are shown at a higher magnification of the white square in the upper panels. Images are representative of three independent experiments. Scale bars, 5 μm.

**FIGURE 6.** In vivo binding of NFAT1 and JunB to the IL-31 promoter locus. (A and B) ChIP assay was performed with unstimulated (w/o) or PMA/ionomycin-stimulated (P/I) CD4+ T cells using control IgG, anti-NFAT1 Ab (A) or anti-JunB Ab (B). (C) ChIP assay was performed with unstimulated (w/o) or PMA/ionomycin-stimulated (P/I) CD4+ T cells isolated from WT or NFAT1 KO mice using control IgG or anti-JunB Ab. (D) Activated T cells were transfected with control or JunB siRNA. After 46 h of transfection, cells were stimulated with PMA/ionomycin for 2 h and harvested to analyze NFAT1 binding. The amounts of precipitated DNA were measured by qRT-PCR with primers specific for the indicated NFAT/JunB binding regions (−116/−54, −359/−242) in the IL-31 promoter locus (A–D) and negative control locus (−1374/−1179) (C and D). Relative enrichment of the IL-31 promoter in the precipitated samples compared with total chromatin (input) is shown. Negative images of ethidium bromide–stained gels are also shown in the right panel. C-siRNA, control siRNA; J-siRNA, JunB siRNA. Error bars indicate SD. Data are representative of three independent experiments. *p < 0.05, **p < 0.005.
by PMA/ionomycin stimulation (Fig. 6A, 6B). Next, we examined whether the binding of NFAT1 and JunB to the IL-31 promoter region was dependent on one another. To address this question we first compared the binding of JunB to the IL-31 promoter in WT CD4+ T cells and NFAT1-deficient CD4+ T cells with or without PMA/ionomycin stimulation. Compared to WT, in NFAT1 KO CD4+ T cells, the binding of JunB to the IL-31 promoter was significantly decreased in only the unstimulated condition (Fig. 6C). We also examined the effect of JunB-dependent NFAT1 binding to the IL-31 promoter by knockdown of JunB expression with siRNA treatment. Binding of NFAT1 to the IL-31 promoter was significantly reduced in JunB siRNA–treated cells as compared with control siRNA–treated cells (Fig. 6D). These results indicate that binding affinity of NFAT1 and JunB to the IL-31 promoter is moderately affected by one another.

To further confirm the physical binding of NFAT1 to the IL-31 promoter, a DAPA was performed. Three probes for NFAT1 binding sites were designed based on their highest matrix similarity (0.8): NFAT-a (−83/−56), NFAT-b (+91/+120), and NFAT-c (+119/+148) (Fig. 3B). A biotinylated NFAT-a (−83/−56) probe efficiently pulled down NFAT1 protein from NFAT1-transfected HEK-293 cell lysate (lane 3 in Fig. 7A). Addition of nonbiotinylated competitor probes for NFAT-a (−83/−56), NFAT-b (+91/+120), and NFAT-c (+119/+148) or consensus NFAT probe significantly reduced the pulldown efficiency (lanes 4–7 in Fig. 7A). However, mutant probes such as mtNFAT-a (−83/−56), mtNFAT-b (+91/+120), mtNFAT-c (+119/+148), and mutated consensus competitor probe failed to inhibit the binding of biotinylated NFAT-a probe (lanes 8–11 in Fig. 7A). These results confirmed a physical binding of NFAT1 to the IL-31 promoter. We also confirmed the binding of JunB to the predicted JunB binding sites at the IL-31 promoter. The biotinylated AP-1–a (−100/−71) probe effectively pulled down the JunB protein from JunB-transfected HEK-293 cell lysate in a dose-dependent manner (Fig. 7B).

NFAT1 and JunB cooperatively upregulate IL-31 gene expression in primary T cells

To further investigate the functional involvement of NFAT1 and JunB in IL-31 gene expression, primary CD4+ T cells were transfected with NFAT1 and JunB expression plasmids, and the IL-31 transcript level was measured by qRT-PCR. Transfection of NFAT1 or JunB alone increased IL-31 expression by 6- and 3.2-fold, respectively, compared with control cells (Fig. 8A). Overexpression of both NFAT1 and JunB further increased the IL-31 expression level by 9.8-fold compared with control cells (Fig. 8A). We also tested the knockdown effect of NFAT1 and JunB by siRNA on IL-31 expression. Treatment of siRNA for NFAT1 specifically inhibited the expression of NFAT1 without affecting the expression of other NFAT family members (NFAT2 and NFAT4) (Fig. 8B). Activated CD4+ T cells were transfected with siRNAs for NFAT1 (Fig. 8C), JunB (Fig. 8D), or mock control, and their effects on IL-31 expression were analyzed. Indeed, knockdown of NFAT1 significantly reduced IL-31 mRNA levels (~40% reduction in Fig. 8E), whereas knockdown of JunB alone failed to do so. Interestingly, however, knockdown of both NFAT1 and JunB significantly reduced IL-31 expression levels (~80% reduction in Fig. 8E). These results indicate that NFAT1 and JunB cooperatively regulate endogenous IL-31 expression in CD4+ T cells. Next, we also examined the effect of NFAT1 and JunB on the IL-31 expression by the treatment of CsA or tanshinone IIA, inhibitors for calcineurin and AP-1, respectively. Indeed, CsA or tanshinone IIA treatment decreased IL-31 mRNA production by 85 and 40%, respectively. Treatment of both CsA and tanshinone IIA further diminished IL-31 levels by up to 90% (Fig. 8F). To further confirm the pivotal role of NFAT1 in IL-31 expression, we tested the effect of NFAT1 deficiency on IL-31 mRNA level. Compared with CD4+ T cells from WT mice, NFAT1-deficient (N1 KO) CD4+ T cells showed a significant decrease in IL-31 mRNA level upon PMA/ionomycin stimulation (Fig. 8G). We also tested whether reconstitution of NFAT1 into NFAT1-deficient CD4+ T cells could restore the IL-31 expression. NFAT1-expressing plasmid was nucleofected to CD4+ T cells derived from NFAT1 KO mice and after 22 h of nucleofection, and cells were stimulated with PMA/ionomycin for 2 h. Reconstitution efficiency of NFAT1 into NFAT1-deficient CD4+ T cells was confirmed by checking the protein level of NFAT1 by Western blotting (Fig. 8H, lower panel). Upon reconstitution of NFAT1 into NFAT1 KO CD4+ T cells, the IL-31 level was partially restored compared with NFAT1 KO CD4+ T cells. Additionally, expression levels of two other well-studied NFAT1 target genes were also partially restored by the reconstitution of NFAT1 to NFAT1 KO CD4+ T cells (Fig. 8H, right two panels). These results indicate a crucial role of NFAT1 for IL-31 expression in CD4+ T cells.

Essential role of NFAT1 for the IL-31 induction in AD condition

The IL-31 level is highly increased in AD patients compared with healthy controls (28–30), and treatment with calcineurin inhibitors such as CsA and FK-506 ameliorates atopic symptoms (26). However, the underlying mechanism of increased IL-31 expression in the AD condition is still unclear. To examine the in vivo relevance of NFAT1-mediated IL-31 gene regulation in the AD condition, we induced experimental AD to ears of BALB/c mice using mite extracts and DNCB. Five weeks after AD induction, CD4+ T cells from normal healthy mice or AD-induced mice were stimulated with PMA/ionomycin or anti-CD3/anti-CD28 for 2 h.
CD4+ T cells were also stimulated with mite extracts (5 μg/ml) in the presence of T cell–depleted splenocytes as APCs for 24 h. Compared with normal CD4+ T cells, CD4+ T cells from AD-induced mice expressed significantly higher levels of IL-31 mRNA upon PMA/ionomycin or anti-CD3/anti-CD28 stimulation (Fig. 9A, left panel) or mite extract (Fig. 9A, right panel). Treatment of inhibitors for NFAT1 (CsA) or AP-1 activity (tanshinone IIA) significantly decreased the IL-31 expression compared with the control (Fig. 9B). We found that IL-31–producing NFAT1+ CD4+ T cells were highly increased in the ears of AD-induced mice as compared with healthy mice (Fig. 9C). We found that non–CD4+ T cells also produced much higher amounts of IL-31 under atopic conditions (Supplemental Fig. 2). We tested whether NFAT1 also regulates IL-31 gene expression in non–CD4+ T cells. Non–CD4+ T cells isolated from WT and NFAT1 KO were stimulated and then relative IL-31 levels were compared. Cells from NFAT1 KO mice showed a significant decrease in the expression level of IL-31 (Supplemental Fig. 3). IL-31 expression was significantly increased in total ear residual cells from AD-induced mice as compared with that of normal mice (Fig. 9D), which was well correlated with increased NFAT1 levels in total cell lysates as well as nuclear extract prepared from total ear cells (Fig. 9E). Increased NFAT1 levels were also found in the cells isolated from the draining lymph nodes and spleen (Supplemental Fig. 4) of AD mice. These results suggest that increased NFAT1 expression in cells mediates the enhanced IL-31 levels in AD condition. We further investigated the functional importance of NFAT1-mediated IL-31 expression in ongoing AD mice. We tested the effect of CsA administration on IL-31 expression under the AD condition. Indeed, oral administration of the microemulsion form of CsA significantly reduced the numbers of IL-31–expressing CD4+ T cells in the AD ears compared with those of control mice (Fig. 9F). Treatment of CsA significantly decreased the expression of IL-31 as well as AD-related pathogenic cytokines such as IL-4, IL-13, and IFN-γ in the ear total cells (Fig. 9G). This result indicates that inhibition of NFAT1 activity suppressed AD development by reducing the IL-31 expression by CD4+ T cells and non–CD4+ T cells as well.

**Discussion**

The main purpose of this study was to elucidate the molecular mechanism of IL-31 gene regulation in CD4+ T cells in health and disease. We identified the TSS and functional promoter region of IL-31 gene. We found that TCR-induced IL-31 expression is mediated by a functional cooperation between two transcription factors.
NFAT1 and JunB (AP-1). Physical binding of NFAT1 and JunB to the IL-31 promoter region increased its transcriptional activity. Under atopic conditions, enhanced infiltration of NFAT1+CD4+ T cells on the AD ears was well correlated with a significant increase of IL-31 expression. Treatment of inhibitors for NFAT1 and JunB (AP-1) significantly decreased IL-31 expression in CD4+ T cells of AD mice. Our results suggest that NFAT1 and JunB cooperatively regulate the IL-31 transcription in CD4+ T cells in both normal and AD conditions.

Functional importance of IL-31 in diverse immune disorders has been suggested (27–31). However, the underlying mechanism of IL-31 expression at the transcriptional levels is still unclear. In this study, we have identified the TSS (Fig. 2C) and functional promoter region, located between the region −359 and +141 of the IL-31 gene (Fig. 3C). A previous study on human IL-31 reported a functional promoter region in CD4+ T cells and mast cells (32) without revealing an exact TSS. We compared human and mouse promoter regions and transcription factors responsible for the activation of promoters (Supplemental Fig. 1A). The human IL-31 promoter (827 bp) contains conserved binding sites for several transcription factors such as NFAT, STAT6, AP-1 and NF-kB. Among the factors, NFAT2 and STAT6 played a major role in activation of its promoter activity (32). We also tested whether NFAT2 and STAT6 could activate mouse IL-31 promoter as well. However, NFAT2 and STAT6 failed to activate mouse IL-31 promoter whereas NFAT1 alone sufficiently activated the mouse promoter region, located between the region −359 and +141 of the IL-31 gene (Fig. 3C). A previous study on human IL-31 reported a functional promoter region in CD4+ T cells and mast cells (32) without revealing an exact TSS. We compared human and mouse promoter regions and transcription factors responsible for the activation of promoters (Supplemental Fig. 1A). The human IL-31 promoter (827 bp) contains conserved binding sites for several transcription factors such as NFAT, STAT6, AP-1 and NF-kB. Among the factors, NFAT2 and STAT6 played a major role in activation of its promoter activity (32). We also tested whether NFAT2 and STAT6 could activate mouse IL-31 promoter as well. However, NFAT2 and STAT6 failed to activate mouse IL-31 promoter whereas NFAT1 alone sufficiently activated the mouse
IL-31 promoter in a STAT6-independent manner (Supplemental Fig. 1B). Interestingly, the STAT6 binding site identified in the human IL-31 promoter was matched with Nfat binding sites of the mouse IL-31 promoter (Supplemental Fig. 1A). This finding suggests that NFAT may play a crucial role in regulation of IL-31 expression both in humans and mice although different NFAT family members are responsible for activation of the IL-31 promoter. Indeed, Nfat2 and Nfat4 also showed transactivation on mouse IL-31 promoter, although NFAT1 showed the strongest activity (Fig. 4A). Functional synergism between Nfat/AP-1 interaction has been reported in regulation of diverse NFAT target genes such as IL-2, IL-4, IL-5, IL-13, and INF-γ (18, 33, 34). In this study we also found that whereas NFAT1 alone significantly regulated IL-31 promoter activity, AP-1 binding had a positive contribution (Fig. 4C). Deleting (Fig. 4E) or mutating (Fig. 4F) Nfat or AP-1 binding sites or treating them with their inhibitors (Fig. 8F) significantly reduced IL-31 promoter activity as well as IL-31 mRNA expression. Additionally, disruption of physical interaction between NFAT1 and AP-1 abolished the synergistic transactivation on the IL-31 promoter (Fig. 4D). These results collectively suggest a functional synergism of NFAT1/AP-1 interaction in IL-31 gene regulation.

Pathophysiological role of IL-31 has been reported in diverse immune disorders, including AD (32–35). Compared with normal healthy people, a significant increase in IL-31 levels was observed in AD patients along with the upregulation of IL-4 and IL-13 (29). Enhanced IL-31 levels from Th2 cells activated IL-31RA−/− expressing neurons, which induced a T cell–mediated itching behavior (29, 36). Additionally, IL-31 induces the upregulation of AD-associated pathogenic cytokines (TNF-α, IL-6, and IL-1β) and chemokines (CCL20, CCL2, CCL5, CXC1L, CCL18, and CCL22) by dendritic cells, macrophages, epithelial cells, eosinophils, and keratinocytes (4, 37, 38). In this study, we also found that CD4+ T cells isolated from AD mice showed a significant increase of IL-31 expression upon TCR- or allergen (mite extract)–specific stimulation (Fig. 9) mainly in draining lymphocytes (Supplemental Fig. 4). Immunostaining of IL-31 on sections of AD ear showed that although CD4+ T cells are the main source of IL-31, non–CD4+ T cells also produce large amount of IL-31 as well. Compared with normal mice (Supplemental Fig. 3). These results imply that NFAT1 plays a crucial role for IL-31 gene expression in both CD4+ T cells and non–CD4+ T cells. However further studies are required to identify which kind of NFAT proteins play a key role in regulation of IL-31 expression in non–CD4+ T cells. Interestingly, severity of AD symptoms was well correlated with NFAT1+ signal and IL-31 expression both in CD4+ T cells and in non–CD4+ T cells. CsA, an inhibitor of Ca2+/calmodulin/calcineurin/NFAT signaling had been used to treat AD-associated pathogenic cytokines (TNF-α, IL-5, IL-13, and INF-γ) by dendritic cells, macrophages, epithelial cells, eosinophils, and keratinocytes (4, 37, 38).

In summary, we demonstrated that NFAT1 plays a key role in regulation of IL-31 gene expression in both CD4+ T cells and non–CD4+ T cells. This study further extends previous studies of NFAT family members as regulatory factors in diverse immune disorders.


Supplemental Figure 1. Comparison of the mouse and human IL-31 promoter regions. A, sequence of mouse IL-31 promoter region. Identified crucial functional binding sites for NFAT and STAT6 in the human IL-31 promoter are marked in red. Binding sites for NFAT (NFAT-a/ NFAT-b/ NFAT-c), AP1/AP1-a/ AP1-b) and STAT6 (STAT6-a/ STAT6-b/ STAT6-c/ STAT6-d/ STAT6-e/ STAT6-f) in the mouse promoter region is boxed in black. B, EL4 T cells were transfected with luciferase reporter constructs containing the mouse IL-31 promoter region with expression plasmids encoding NFAT1, NFAT2, or STAT6 as indicated. Cells were stimulated with PMA/ionomycin for 6 hrs and harvested for the luciferase assay. Relative luciferase activity (RLA) of each sample to control sample (mock) is presented. Error bars indicate SD. One (*) indicates p<0.05. Data are representative of three independent experiments.
Supplemental Figure 2. Enhanced IL-31 by CD4⁺ and non-CD4⁺ in atopic ear region. A-B, qRT-PCR analysis of IL-31 mRNA expression in draining lymph nodes (dLN) (A) and atopic ear (B) was performed with the CD4⁺ T cells and non-CD4⁺ T cells of mice under normal (Nor) and AD condition. HPRT was used as an internal control. Error bars indicate SD. One (*) or two (**) indicates p<0.05 and p<0.005 respectively. Data are representative of three independent experiments.
**Supplemental Figure 3.** NFAT1 regulates *IL-31* gene expression in non-CD4*+* T cells. Non-CD4*+* T cells isolated from wild type (WT) or NFAT1 deficient (N1KO) mice were stimulated with PMA/ionomycin for indicated times and subjected to qRT-PCR analysis. Mouse HPRT was used as an internal control, and relative IL-31 ratio to unstimulated WT sample was presented. Error bars indicate SD. One (*) or three (***)) indicates p<0.05, and p<0.005 respectively. Data are representative of three independent experiments.
Supplemental Figure 4. Lymph nodes are main producers of NFAT1 in AD induced mice. A, Cells were isolated from draining lymph nodes (LN) and spleen (SP) from the mice under normal (Nor) and AD condition (AD), then IL-31 mRNA level was measured by qRT-PCR. Mouse HPRT was used as an internal control and relative IL-31 ratio was presented. B, Protein level of NFAT1 in total cell lysates (TCL) and nuclear extracts (N.E) of LN or SP isolated from normal and AD induced mice was examined by Western blot. β-actin and Lamin B were used as a loading control, respectively. Error bars indicate SD. One (*) or two (**) indicates p<0.05 and p<0.005 respectively. Data are representative of three independent experiments.